Genprex Reaches Deal with Aldevron for More Plasmid DNA for Expanding Clinical Program

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive’s Christine Corrado at the MicroCap Conference in New York. The clinical-stage gene therapy company has reached a deal with Aldevron, a contract manufacturer, to receive a supply of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in its clinical…

Learn More

Genprex CEO Updates Investors on $10mln Capital Raise Progress of Oncoprex

Genprex (NASDAQ:GNPX) CEO Rodney Varner updates Proactive’s Christine Corrado on the Austin, Texas-based biopharma’s operations in the last few months, notably raising $10mln to be used toward continuing the company’s clinical trial of Oncoprex,. Enrollment in Phase 1 and 2 studies for the cancer fighting drug has resumed…

Learn More

Genprex Making Strides to Take Cancer-Fighting Drug Oncoprex to FDA approval

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the bio-pharmaceutical company is making great strides toward developing the company’s non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex. Varner says Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about…

Learn More

Genprex Developing the First Immunogene Therapy for the Treatment of Cancer

Julien Pham, MD, MPH and COO of Genprex, Inc. details our lead product candidate, Oncoprex™ (currently in development and not FDA approved). It uses a revolutionary approach to cancer treatment that combines the features of Gene Therapy, Immunotherapy, and Nanotechnology to harness the body’s own mechanisms to fight cancer.

Learn More